[{"Assets_0_Q1_USD":340719000.0,"CommonStockSharesOutstanding_0_Q1_shares":19150000.0,"EarningsPerShareBasic_1_Q1_USD":0.61,"EarningsPerShareDiluted_1_Q1_USD":0.59,"NetIncomeLoss_1_Q1_USD":11693000.0,"StockholdersEquity_0_Q1_USD":317579000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":19918000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":19130000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20171231","fy":"2018.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180209"}]